1. Home
  2. BIRD vs AYTU Comparison

BIRD vs AYTU Comparison

Compare BIRD & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allbirds Inc.

BIRD

Allbirds Inc.

HOLD

Current Price

$3.15

Market Cap

28.8M

ML Signal

HOLD

Logo Aytu BioPharma Inc.

AYTU

Aytu BioPharma Inc.

HOLD

Current Price

$2.30

Market Cap

25.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIRD
AYTU
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.8M
25.7M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
BIRD
AYTU
Price
$3.15
$2.30
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$11.00
$9.33
AVG Volume (30 Days)
60.9K
64.5K
Earning Date
01-01-0001
05-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$189,757,000.00
$27,632,080.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$44.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
277.47
52 Week Low
$2.90
$0.95
52 Week High
$12.84
$3.07

Technical Indicators

Market Signals
Indicator
BIRD
AYTU
Relative Strength Index (RSI) 25.91 43.99
Support Level $2.96 $2.13
Resistance Level $3.21 $2.50
Average True Range (ATR) 0.23 0.15
MACD -0.02 -0.02
Stochastic Oscillator 16.06 28.57

Price Performance

Historical Comparison
BIRD
AYTU

About BIRD Allbirds Inc.

Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.

Share on Social Networks: